Journey Medical Corp

NASDAQ:DERM

Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company provides nine products that help treat and heal common skin conditions, such as Qbrexza, Accutane, Targadox, Ximino, Exelderm Cream and Solution, Ceracade Skin Emulsion, Luxamend Wound Cream, AMZEEQ and ZILXI. Its product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne; Exelderm Cream and Solution is an antifungal intended for topical use; Ceracade Skin Emulsion is used to treat dry skin conditions; AMZEEQ is used for the treatment of acne and ZILXI, for the treatment of rosacea.